Compare Merck & Co., Inc. (MRK) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NICE Ltd — how do they compare? Merck & Co., Inc. trades at $142.3 (market cap $352.29B), while NICE Ltd trades at $117 (market cap $6.83B). The key difference: Merck & Co., Inc. is far larger — about 51.6× NICE Ltd's market cap, and Merck & Co., Inc. pays a 2.38% dividend while NICE Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and NICE Ltd for 15 Days on average.
| MRK | NICE | |
|---|---|---|
Market Cap | $352.29B | $6.83B |
Volume | 6,348,796 | 444,610 |
Sector | Health | Technology |
52-Week High | $156.43 | $137.68 |
52-Week Low | $82.49 | $83.15 |
Typical Hold Time | 98 Days | 15 Days |
Enterprise Value | $399.05B | $6.57B |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
NICE (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $2.95 billion in 2025, though net income is projected to decline in 2026. Recent news highlights leadership in AI-driven contact center platforms and positive institutional buying interest.
The outlook for NICE is positive, supported by AI revenue growth and a reasonable valuation, but investors face risks from margin compression and earnings volatility. The stock's proximity to resistance at $118 suggests near-term consolidation may occur before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
